Analytics Start-Up Brings Innovation To Clinical Trials (Article in BusinessBecause)

Business BecauseAn article written by Seb Murray using his specific business-friendly and concise style about Cyntegrity and its founders:

“The evolution of clinical trials, with increases in globalization, study complexity and technological capabilities, means there is a need to bring innovative approaches to drug development. Artem Andrianov, a Cass Business School MBA, is making that a reality.


The Frankfurt-based venture is poised to benefit from regulatory changes, which will facilitate innovation in clinical trials, including risk-based monitoring and the use of technological tools to ensure robust oversight and reporting. New regulation to usher in these changes was endorsed by the Steering Committee of the ICH, the global umbrella of regulatory authorities, last year.”

Read more here:


By |2016-11-16T18:35:45+00:00June 2, 2015|News|0 Comments

About the Author:

Professional in the integration of data-driven Risk-based Monitoring (RbM) process in international clinical trials of pharmacology. Speaker at regional and global conferences such as: DIA, PharmaForum, PharmaDay, DGGF, etc. 10+ years of experience in data quality projects and biostatistics for the pharmaceutical industry. Life passion: improving clinical research with RbM, driving the RbM research to new frontiers for CROs, pharma and biotech companies.

Leave A Comment

Upcoming Events

  1. PCT Europe 2018

    November 28 - November 29

Register Today!

Get Free Test Access